TF and cancer: Although, normally, the holo-Tf/apo-Tf ratio was determined in the range of 30–55%/45–70% (Figure 3 shows the result for only one cancer-free woman’s sample, 3K1, with the highest holoTf content), in CrO, this ratio is 10–23%/77–95% (demonstrated for eight samples from patients with CrO).